Clinical Trial

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-12-19; most recent amendment 2026-01-21.
Status change: Recruiting → Active, Not Recruiting 2023-11-13
Status change: Not Yet Recruiting → Recruiting 2020-01-03
Trial Details
NCT Number NCT04208347
Lead Sponsor Ruijin Hospital
Conditions Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment 580 participants
Start Date 2019-12-18
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-23